New pill aims to slow Alzheimer's: phase 2 trial underway

NCT ID NCT07252440

Recruiting now Disease control Sponsor: Shanghai Auzone Biological Technology Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 17, 2026 · Updated 3 times

Summary

This Phase 2 trial tests whether TTYP01 tablets can slow cognitive decline in people with early Alzheimer's disease. About 180 participants aged 60-85 with mild cognitive impairment or mild dementia will receive either a low dose, high dose, or placebo for 78 weeks. Researchers will measure changes in memory tests, brain scans, and blood markers to see if the drug is safe and effective.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TTYP01 tablets
What this could lead to: If successful, TTYP01 could slow cognitive decline in early Alzheimer's, offering a new treatment option for patients.
What could go wrong: This is an early Phase 2 trial with only 180 participants. The drug may not show benefit over placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AD EARLY ALZHEIMER'S DISEASE

Contacts and locations

Locations

Daping Hospital.
RECRUITING

Chongqing, Chongqing Municipality, 400042, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.